Role Of Bradykinin

FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Share / Send / Save

HAE attacks are characterized by elevated bradykinin levels that lead to episodes of edema1

C1-INH is involved in regulating several metabolic cascades leading to swelling.2 The lack of functional C1-INH in HAE leads to the excessive release of bradykinin.3 Literature shows that local bradykinin concentrations are elevated in patients during an acute HAE attack.1,4-6

Pathway leading to generation of bradykinin7

Illustration of the pathway leading to a generation of bradykinin. Patients with HAE have an underlying deficiency in functional C1-INH that leads to an overproduction of bradykinin.

C1-INH regulates the production of bradykinin.7 Patients with HAE have an underlying deficiency in functional C1-INH that leads to an overproduction of bradykinin.8,9

Bradykinin: A symptom-causing mediator of HAE attacks8,10

Illustration of how bradykinin activates BK2 receptors during a hereditary angioedema attack.

HAE attacks result from the overactive production of bradykinin.8,10

Illustration of how activated BK2 receptors mediate an increase in vascular permeability that can cause swelling and pain.

Activated BK2 receptors mediate an increase in vascular permeability that can cause swelling and pain.3,10,11

FIRAZYR is the only FDA-approved bradykinin BK2 receptor antagonist to treat HAE attacks11,12

Firazyr inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.

FIRAZYR, the only FDA-approved BK2 receptor antagonist, reduces the localized swelling and pain associated with acute HAE attacks.11,12